Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy

Inclusion Criteria: * Male or female 75 years of age or older, * Lymphoid hemopathies (diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, Hodgkin's lymphoma and T-cell lymphoma, chronic lymphocytic leukemia (CLL)) or plasma cell and/or lymphoplasmacytic hemopathies (multiple myeloma or Waldenström disease). * World Health Organization (WHO) performance index 0-3, * Patients requiring first or second line chemotherapy and/or immunotherapy associated or not to targeted therapy, * Patients with a life expectancy of more than 3 months, * Persons affiliated or benefiting from a social insurance, * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Myeloid hemopathies, * Patient included in a clinical trial that potentially interferes with the purpose of the study (geriatric interventional study, early drug study), * Patient under court protection, guardianship or curator